City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗

2021-04-06 国际文传 国际文传

癌症和糖尿病独立研究和治疗中心City of Hope宣布将与癌症治疗中心Hospital Israelita Albert Einstein签订协议从而将双方领先的癌症治疗专长带到南美洲。

世界知名的癌症和糖尿病独立研究和治疗中心City of Hope今天宣布,该中心将与拉美地区顶级癌症治疗中心Hospital Israelita Albert Einstein签订教育培训协议,从而将其领先的癌症治疗专长带到南美洲。 

根据这项为期三年的协议,City of Hope将与Hospital Israelita Albert Einstein的肿瘤科住院医师和临床工作人员分享其癌症治疗方面的专长。City of Hope将提供教育经验,并主持多学科肿瘤委员会。双方将在精准肿瘤学和相关研究方面深入探索创新合作的可能性。

总部位于洛杉矶近郊的City of Hope的战略与商业事业部总裁Harlan Levine, M.D.表示:“这项协议标志着另一个里程碑时刻,让City of Hope将其消除癌症的使命延伸到新的大陆。”

Levine补充道:“Hospital Israelita Albert Einstein拥有一支出色的医疗团队。City of Hope将为这家医院的受训住院医师和临床工作人员提供我们作为一家综合癌症治疗中心所具备的一流专业知识。我们希望与拉美地区的同仁通力合作,改善圣保罗乃至整个巴西和拉美地区的癌症护理效果。”

City of Hope还将提供多种其他服务,包括成立在线召开会议的多学科肿瘤委员会,该委员会最初的关注点将集中在胃肠道疾病、泌尿生殖系统疾病、肺癌和脑癌的治疗方面。Hospital Israelita Albert Einstein的医生将分享具体的患者病例,涉及分子诊断免疫治疗和癌症护理服务创新等复杂问题,以供评议和讨论。City of Hope还将提供教育性质的网络研讨会,并就基因检测、支持性护理服务和护理等主题提供专业培训。

Hospital Israelita Albert Einstein院长Sidney Klajner, M.D.博士表示:“我们将结合City of Hope的多学科肿瘤精准医疗方法,以缓解巴西目前的癌症治疗负担。我们希望与City of Hope在分子诊断和创新护理方面通力合作,造福拉美及其他地区的患者。”

Hospital Israelita Albert Einstein已连续12年被《美洲经济》(America Economia)杂志的商业情报部门评为拉丁美洲顶级医院。此外,在《新闻周刊》(Newsweek)发布的“2021年世界顶级医院”排名中,该医院在全球总排名第36位,肿瘤学专科领域排名第21位。

此次合作协议是在City of Hope的国际医学中心(CIM)努力下促成的,该中心力求与国际组织合作,为全球更多的人改善癌症和糖尿病治疗。CIM与政府、医院、私营公司和投资者合作,在临床研究和创新、教育和专业发展等领域提供一系列服务。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728900, encodeId=98061e28900ce, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Feb 17 06:13:47 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738599, encodeId=24921e3859917, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Nov 19 00:13:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844310, encodeId=423f184431004, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 12 08:13:47 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977603, encodeId=49e019e7603a3, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jul 08 02:13:47 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941537, encodeId=feb7194153e8e, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4775, encryptionId=64c94e75a3, topicName=City)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sun Jul 11 01:13:47 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
    2022-02-17 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728900, encodeId=98061e28900ce, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Feb 17 06:13:47 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738599, encodeId=24921e3859917, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Nov 19 00:13:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844310, encodeId=423f184431004, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 12 08:13:47 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977603, encodeId=49e019e7603a3, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jul 08 02:13:47 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941537, encodeId=feb7194153e8e, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4775, encryptionId=64c94e75a3, topicName=City)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sun Jul 11 01:13:47 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728900, encodeId=98061e28900ce, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Feb 17 06:13:47 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738599, encodeId=24921e3859917, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Nov 19 00:13:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844310, encodeId=423f184431004, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 12 08:13:47 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977603, encodeId=49e019e7603a3, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jul 08 02:13:47 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941537, encodeId=feb7194153e8e, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4775, encryptionId=64c94e75a3, topicName=City)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sun Jul 11 01:13:47 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728900, encodeId=98061e28900ce, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Feb 17 06:13:47 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738599, encodeId=24921e3859917, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Nov 19 00:13:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844310, encodeId=423f184431004, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 12 08:13:47 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977603, encodeId=49e019e7603a3, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jul 08 02:13:47 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941537, encodeId=feb7194153e8e, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4775, encryptionId=64c94e75a3, topicName=City)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sun Jul 11 01:13:47 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
    2021-07-08 drj2003
  5. [GetPortalCommentsPageByObjectIdResponse(id=1728900, encodeId=98061e28900ce, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Feb 17 06:13:47 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738599, encodeId=24921e3859917, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Nov 19 00:13:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844310, encodeId=423f184431004, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 12 08:13:47 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977603, encodeId=49e019e7603a3, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jul 08 02:13:47 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941537, encodeId=feb7194153e8e, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4775, encryptionId=64c94e75a3, topicName=City)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sun Jul 11 01:13:47 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
    2021-07-11 nakerunner

拓展阅读

教科书级新发现:调控基因表达的“交通灯”,将为癌症治疗提供新靶点

近日,一篇发表在Nature上的重要研究揭示了组蛋白修饰的一种“交通灯”机制,可以控制细胞内的基因活动,并有望成为现有癌症药物开发的靶点。

迎接RNA疗法的时代

以RNA为基础的疗法逐渐成为各种疾病的潜在干预策略。

Nature:首次使用CRISPR向T细胞插入新抗原治疗癌症,为个性化癌症治疗铺平道路

CAR-T细胞疗法已经在血液类肿瘤中取得了令人惊喜的治疗效果,FDA也已经批准了多款CAR-T疗法上市。然而,CAR-T在治疗实体瘤方面仍然存在挑战。其中一个原因是CAR-T细胞附着于肿瘤外部,不易向

Nature子刊:热量限制完胜!减缓肿瘤进展转移,增强免疫能力!

Nat Commun:无论饮食成分如何,每日热量限制比热量循环更有效地限制了肿瘤的生长

平衡痴呆症患者癌症治疗中个人需求与服务需求

为痴呆症患者提供以人为中心的护理时,护理结局和满意度提高。

2022 WALT意见书:光生物调节疗法在癌症治疗引起的副作用管理中的应用

世界光生物调节治疗协会(WALT,World Association of photobiomodulation Therapy) · 2022-08-30

2022 ASCO 指南:癌症治疗期间的运动、饮食和体重管理

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2022-05-16

2020 MASCC/ISOO临床实践指南:癌症治疗继发性粘膜炎的管理

癌症支持疗法多国学会(MASCC,Multinational Association of Supportive Care in Cancer) · 2020-07-28

2016 ESC意见书:癌症治疗与心血管毒性

欧洲心脏病学会(ESC,European Society of Cardiology) · 2016-08-26